Core Viewpoint - The company has received acceptance for the listing application of its semaglutide injection, aimed at controlling blood sugar levels in adults with type 2 diabetes, from the National Medical Products Administration of China [1] Group 1: Product Development - The semaglutide injection is a GLP-1 receptor agonist developed based on the natural structure of human glucagon-like peptide-1, classified as a new drug under category 2.2, which contains known active ingredients and demonstrates significant clinical advantages [1] - The application is based on a pivotal phase III clinical trial, which showed that the product exhibited highly consistent efficacy compared to Novo Nordisk's semaglutide in patients with poorly controlled blood sugar after metformin treatment, with slightly lower gastrointestinal reaction rates [1] Group 2: Clinical Value and Future Prospects - The product has significant clinical application value due to its advantages in efficacy, safety, and formulation [2] - The company is actively advancing phase III clinical trials for the product targeting obesity/overweight indications, aiming to benefit more patients [2]
石药集团(01093.HK)：司美格鲁肽注射液的上市申请获国家药品监督管理局受理